Erlotinib hydrochloride.
Dowell
Jonathan
J
Minna
John D
JD
Kirkpatrick
Peter
P
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000453:epidemiology; D017326:Clinical Trials, Phase III as Topic; D000077143:Docetaxel; D004334:Drug Administration Schedule; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D066246:ErbB Receptors / Q000145:classification / Q000187:drug effects / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D005104:Expert Testimony; D006801:Humans; D011799:Quinazolines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors